Nancy Stagliano

Nancy is CEO and Chair of the Board of Neuron23, Inc., a South San Francisco–based precision neurology and immunology therapeutics company. An experienced CEO, Nancy has led True North Therapeutics (acquired by Bioverativ in 2017), iPierian (acquired by BMS in 2014), and CytomX Therapeutics (CTMX). With more than 20 years of experience in the biotechnology industry, Nancy’s career path has always stayed close to the science, beginning with 7+ years at Millennium Pharmaceuticals in Cambridge, MA, in the discovery organization.

Nancy is Chair of the Board of Latigo Bio, a Thousand Oaks–based biotech focused on non-opioid pain medicines. Nancy also serves as a director on the not-for-profit board of PanCAN, the Pancreatic Cancer Action Network. In the past, Nancy has also advised venture capital firms Westlake Village BioPartners and New Leaf Ventures.

Nancy has a PhD in Neuroscience from the University of Miami School of Medicine, an MS in Biomedical Engineering, and a BS in Electrical Engineering, both from Drexel University.